interaction with viral gene products (Banks et al, 1995; Kubbutat and Vousden, 1996) . Therefore, in the pathogenesis of cervical carcinoma we can identify three major factors. Two of them are related to the HPV presence, the effects of viral E6 and E7 proteins, and the consequences of HPV DNA integration in the cellular genome. The third factor is the accumulation of cellular genetic damage, not related to HPV, needed for tumour development (Tomlinson et al, 1996; Lengauer et al, 1998) .
CONSEQUENCES OF INTEGRATION ON VIRAL GENES
Viral DNA integrated into host genome is found in all cases of cervical carcinoma (Bosch et al, 1995) , their metastasis and derivative cell lines (Cullen et al, 1991) . This viral DNA integration is in itself a mutation with consequences both on viral and cellular genome. Cells carrying integrated viral DNA grow better in vitro, and integration has been correlated with a poor prognosis, and development of resistance to treatment (Unger et al, 1995; Vernon et al, 1997; Kalantari et al, 1998) . In the case of cervical carcinoma the integration of viral DNA can contribute to two aspects where HPV is implicated in the CC phenotype. The different consequences of HPV integration either on viral or cellular genome, reflecting the common characteristics of independent CC, are outlined in Table 1 .
From the viral perspective there is only a small deletion of DNA, rarely being more than three kilobases, and retention of specific viral genes. The integrated HPV DNA is linearized between the E1 and L1 genes, in such a way that the viral regulatory region and the E6 and E7 genes are expressed from viral promoters, but with a different regulation, in which cellular factors might play an important role (Gloss et al, 1989; Rosl et al, 1991; Bartsch et al, 1992; O'Connor et al, 1996) . From these hybrid viral-cellular aberrant RNA messages, normal E6 and E7 proteins are synthesized. There is also the loss, by break or deletion, of the viral E2 gene, that normally functions as a positive and/or negative regulator of transcription. Furthermore, the cellular DNA might have undergone complex rearrangements and deletions which are sometimes very large (Gallego and Lazo, 1995; Bauer-Hoffman et al, 1996; Gallego et al, 1997) . Figure 1 Dual effect of HPV E6 and E7 proteins on the cell cycle. Possible mechanism by which HPV E6 and E7 protein can functionally mimic a state of deficiency of p53 and Rb tumour suppressor proteins. The viral proteins promote the ubiquitin-mediated degradation of both tumour suppressor proteins releasing brakes of cell cycle progression and facilitating the expression of genes also needed for completion of the cell cycle
Effects of viral E6 and E7 proteins
The effects of E6 and E7 viral genes have been extensively studied (Kubbutat and Vousden, 1996) . These two viral genes are always retained and overexpressed in CC, and therefore are supposed to contribute to the tumour phenotype. The E6 and E7 proteins have been shown to induce immortalization of different cell types, such as fibroblasts (Pirisi et al, 1987) and human keratinocytes (Smith et al, 1992) . In keratinocytes, immortalized with HPV and expressing E6 and E7, there is an alteration of the balance between proliferation and cell death (Smith et al, 1992) , which suggests that the functions of E6 and E7 are to expand a cell population because of their effect on immortalization, probably as a consequence of their effects on apoptosis (Thomas et al, 1996; Iglesias et al, 1998; Stoppler et al, 1998) . In order for these proteins to induce cellular transformation, by in vitro parameters, they require the cooperation of other genes (Kubbutat and Vousden, 1996) , such as the co-transfection with the H-ras oncogene .
The E6 protein interacts with the p53 tumour suppressor protein (Werness et al, 1990 ) theoretically resulting in the functional sequestration of p53 ( Figure 1 ) and targeting it for degradation via the ubiquitin-dependent proteolytic pathway (Thomas et al, 1996) . The binding of E6 to p53 might thus contribute to accumulate additional mutations by allowing progression through the cell cycle before DNA has been repaired, by altering the control checkpoint for DNA integrity in the G1 phase before entering the S phase of the cell cycle. An additional consequence could be the inhibition of apoptosis by the partial effect of p53 levels and of pRb.
The HPV E7 protein interacts with either pRb and the p107-or p130-related proteins (Figure 1 ). This interaction dissociates these proteins from the transcription factor E2F. The free E2F factor can activate transcription of genes that will promote cell cycle progression and cell proliferation (Kubbutat and Vousden, 1996) . E7 can also interact with cellular transcription factors such as AP-1 (Antinore et al, 1996) .
It is important to take into account that high levels of E6 and E7 expression can also be achieved from viral DNA in its extrachromosomal form, therefore in CC there must be additional factors that contribute to the final tumour phenotype and which might be selected, consistent with the long time that occurs between initial infection and tumour appearance. Curiously, benign tumours induced by other HPV types have a higher cell number and shorter tumour formation time than the malignant tumours. Furthermore, other oncogenic viruses, such as adenovirus and SV40, have proteins which interact with p53 and pRb even more efficiently than HPV proteins, yet they do not induce tumours in humans. Therefore, the effects of E6 and E7 may be mediated by a mechanism not yet identified.
Inactivation of viral E2 gene by integration
The viral E2 gene codes for two proteins with a transcriptional regulatory function. The E2 protein has a transcriptional activation domain in the N-terminus and a DNA binding domain in its C-terminus. The E2 gene can be expressed in two forms, a complete protein that is a positive regulator, and a protein with only the DNA binding domain that functions as a repressor (Dowhanick et al, 1995) . The full-length E2 protein induces cell cycle arrest in the S phase, thus allowing the replication of viral DNA, but at the same time resulting in an increase in cellular DNA which might be implicated in the generation of the aneuploidy observed in CC (Dowhanick et al, 1995; Frattini et al, 1997) . Thus the normal E2 increases the viral load of the infected cell (early lesions) and might alter its chromosome number. In integrated viral DNA there is a loss of both types of E2 proteins. After integration, the removal of this brake, will allow the expansion of cells carrying genetic anomalies of different types. The loss of E2 confers better growth properties to the cell . The clinical relevance of the inactivation of the E2 gene was demonstrated by the analysis of 46 patients with HPV DNA integrated and with disruption of the E2 viral gene. This E2 damage was associated with poor prognosis and a significantly shortened disease-free survival of the patient (Unger et al, 1995; Vernon et al, 1997; Kalantari et al, 1998) . Additional evidence for a contributing effect of the E2 loss of function comes from different studies. In cells transfected with HPV16, the viral DNA was integrated in the genome of the host cell, and these cells acquired a growth advantage that could not be explained by the known effects of other retained viral genes, E6 and E7 . Later on, it was demonstrated that the reintroduction of a normal E2 protein, from HPV16 or HPV18, in HeLa cells, suppressed the cell growth of these cells (Dowhanick et al, 1995) . For this effect to take place, both the transactivating and DNA binding domains of this E2 protein have to be intact (Dowhanick et al, 1995) .
Lack of homology between viral and cellular DNA at integration sites and location of HPV DNA integration sites
One of the characteristics of cancer is the presence of recurrent chromosomal alterations associated to a specific type of tumour. These usually take the form of translocations, but also include amplifications, deletions and point mutations. These alterations are rather well characterized in human lymphoid tumours. Whereas in human solid tumours, their characterization lags behind because of the characteristics of the starting material, this has not been an obstacle for the detection of such recurrent chromosomal alteration in most types of cancer (Mitelman et al, 1997) . In this context we can consider the integration of viral DNA in the cellular genome as a type of recurrent alteration in cancers associated to HPV, CC being the most extensively studied. Viral DNA integration is irreversible genetic damage that could affect cellular genes. Several integration sites and their corresponding normal target sequences have been cloned and studied (El Awady et al, 1987; Lazo, 1988b; Choo et al, 1990; Gallego et al, 1997) . Sequence comparisons do not detect any significant homology either between viral and target cellular DNA, or among the different cellular target regions. This lack of homology suggests that it is the result of non-homologous recombination between cellular and viral DNA. It is likely that there might be some preference for chromatin regions where cellular DNA might be more accessible (Popescu et al, 1990) . In this context it is important to note that several integration regions are in chromosomal regions identified as fragile sites (Table 2) (Durst et al, 1987; Popescu et al, 1990; Lazo et al, 1992; Zimonjic et al, 1994) . Direct evidence for integration within a known fragile site has recently been reported for the integration of HPV16 at 3p14.2 (Wilke et al, 1996) , where FRA3B is located, within the FHIT gene (Zimonjic et al, 1997) . In a population of infected cells that individually might have viral DNA integrated in different chromosome regions, those that have integrated the viral DNA in a region that confers a specific phenotype could be selected, with the final result of a non-random pattern from the point of view of the tumour. If that is the case, integration sites in tumour samples should have the integrated viral DNA in regions where there are genes or genetic alterations which most likely have already been associated to some tumour phenotype properties because this phenotype, despite individual tumour differences, is common in general terms to many tumour types.
The locations of mapped HPV integration sites in cervical carcinoma are shown in Table 2 . All coincide with chromosome regions already linked to the tumour phenotype, mainly by translocations. It is worth noting that, despite the small number of cases studied, two chromosomal regions, 8q24 (Durst et al, 1987; Lazo, 1988b; Couturier et al, 1991) and 12q14-15 (Sastre-Garau et al, 1995; Lopez-Borges et al, 1998) , are recurrently affected by both HPV-16 and HPV-18 DNA integrations. Furthermore, some genes have been shown to be directly affected by integrated HPV DNA, such as FHIT in 3p14-21 (Wilke et al, 1996) , MYC in 8q24 (Durst et al, 1987; Lazo, 1988b; Couturier et al, 1991) and JUN-B in chromosome 19p13.2 (Choo et al, 1995) .
RECURRENT CELLULAR GENETIC ALTERATIONS IN CC
Cervical lesions must accumulate an increasing number of mutations as they progress towards malignancy and invasion. Therefore, the identification of recurrent chromosomal alterations is of utmost importance for the understanding of the biology of this cancer. The genetic alterations in CC might be either a consequence of biological selection for specific chromosome locations containing integrated HPV DNA or result from other alterations that are recurrently affected in this tumour. The recurrent genetic alterations might take several forms such as translocations, point mutations, amplifications, viral DNA integrations, mutator phenotypes or LOH. The LOH means that a particular DNA region has been lost, and therefore, if this loss is recurrent in a significant number of cases of a particular tumour type we can conclude that this chromosome region plays a role in that tumour, and is selected because of it (Tomlinson et al, 1996; Tomlinson and Bodmer, 1999) . LOH is generally thought of as an intermediate step in the inactivation of tumour suppressor genes, such as p53 or RB, which requires the inactivation of both alleles in order to display their phenotype. However, in most cases, the LOH reflects a hemizygous situation and its effect might be a dose effect rather than inactivation of a tumour suppressor gene, although both share a common mechanism of inactivation, and hence of detection, of the loss of genetic material. A particular situation might be represented by the possible existence of different alleles of tumour susceptibility gene, if one of the alleles is more effective than others, there might be a loss of the less effective allele, thus dominating the predisposing allele in these tumours.
LOH analysis has been extensively applied to CC leading to the identification of several chromosomal regions that are recurrently affected in this tumour (Table 3) .
LOH at 3p and the FHIT gene in CC
The 3p region has been implicated in ovarian cancer, breast cancer, testicular cancer, lung cancer and renal cell carcinoma, strongly suggesting the presence of a tumour suppressor gene in the region. In CC, a broad region, 3p12-24, was identified as a target for LOH. The combined data show that LOH occurs at an average frequency of 48% (Table 3) , although it varies from study to study depending on the number of markers used (Jones and Nakamura, 1992; Kohno et al, 1993; Karlsen et al, 1994; Mitra et al, 1994a; Mullokandov et al, 1996; Ku et al, 1997; Larson et al, 1997; Chu et al, 1998; Huettner et al, 1998) . These LOH were detected in both squamous cell carcinomas and adenocarcinomas. In some studies the frequency appears to be higher in squamous cell carcinomas (68%) than in adenocarcinomas (42%) (Larson et al, 1997) . LOH in 3p might be an indicator of tumour progression (Table 2) , since its frequency increases from 25% in FIGO stage I cases to 100% in stage IV cases (Larson et al, 1997) . Among the genes from this chromosome region ruled out to be affected by LOH are APEH, D8, GNA12B, ZNF35, RARB, THRB and RAF1 (Kohno et al, 1993) .
Several studies agree that within the region 3p14-p22 there are two subregions where the LOH are concentrated, and frequently both are altered in the same tumour. These two regions are 3p14.2 and 3p21 (Kohno et al, 1993; Karlsen et al, 1994; Mitra et al, 1994a; Larson et al, 1997; Chu et al, 1998) . These data suggest that two tumour suppressor genes are likely to be located in this chromosome region (Huettner et al, 1998; Kersemaekers et al, 1998a) .
Recently the FHIT gene has been identified within the chromosome region 3p14.2, which is altered in several types of tumours, such as lung (Sozzi et al, 1996) , breast (Hayashi et al, 1997) and oesophageal carcinomas (Zou et al, 1997) , but not in others, such as colon carcinoma (Thiagalingam et al, 1996) . These alterations are detected at the cDNA level in the form of exon losses. The FHIT gene spans more than 1 Mb and comprises the FRA3B fragile site (Zimonjic et al, 1997) . It is important to note that integration of HPV16 occurred directly at the FRA3B fragile site when using HPV integration as a marker for potential oncogenic loci in HPV16 immortalized keratinocytes (Wilke et al, 1996) . This integration occurred between exons 4 and 5 (Zimonjic et al, 1997) . The FHIT gene has been specifically studied in cervical carcinomas (Greenspan et al, 1997; Chu et al, 1998; Muller et al, 1998; Yoshino et al, 1998) . Aberrant FHIT transcripts were detected in seven out of 11 (63%) CC cell lines and in 35 out of 74 (47%) primary cervical carcinomas of different types and stages (Muller et al, 1998) . The aberrant transcripts usually are coexpressed together with a normal transcript. This loss of normal transcript was correlated with a significant loss of FHIT protein by inmmunohistochemistry. In 25 out of 33 primary tumours there was no detectable FHIT protein, while high levels were detected in normal non-neoplastic squamous and glandular cervical epithelium (Greenspan et al, 1997) . In another study of 57 cases, aberrant FHIT mRNA was detected in 9/29 (31%) of the cases, but in normal tissues similar aberrant transcripts were detected in 12/31 of the cases. Therefore it appears that FHIT exon skipping may not be a specific property of the tumour cell (Chu et al, 1998) . The FHIT gene is not a typical tumour suppressor gene (Le Beau et al, 1998) , and the mechanism by which it might contribute to the tumour phenotype is not known (Mao et al, 1996) .
In the 3p21 region the affected gene is not known. This region has the hMLH1 gene, responsible for a mutator phenotype. This gene does not show LOH and is unlikely to be mutated in CC because the frequency of the mutator phenotype in CC is one order of magnitude lower than the LOH frequency. Another candidate gene in the region is β-catenin, but its implication in CC has also been ruled out (Kersemaekers et al, 1998a) . LOH at 3p21 appears to correlate with high mitotic activity (Kersemaekers et al, 1998a) .
The importance of chromosome 3 region in CC is consistent with previous studies in experimental systems. Human Yokota et al, 1989; Jones and Nakamura, 1992; Kohno et al, 1993; Karlsen et al, 1994; Mitra et al, 1994a; Mullokandov et al, 1996; Ku et al, 1997; Larson et al, 1997; Chu et al, 1998; Huettner et al, 1998; Kersemaekers et al, 1998b 4p16 27/66 40 Hampton et al, 1996; Mullokandov et al, 1996; Kersemaekers et al, 1998b 4q21-35 23/72 32 Mitra et al, 1994a; Mullokandov et al, 1996; Kersemaekers et al, 1998b 5p13-15 20/117 17 Ku et al, 1977; Mitra et al, 1994a; Mullokandov et al, 1996; Kersemaekers et al, 1998b 6p21.3-22 60 keratinocytes immortalized with HPV-16 DNA show LOH at 3p. The tumorigenicity of these cells in nude animals correlated very well with instability and loss of genetic material from human chromosome 3p (Montgomery et al, 1995; Steenbergen et al, 1996) , 10p, 11q and 18q regions (Montgomery et al, 1995; Steenbergen et al, 1995 Steenbergen et al, , 1996 . If these regions are the same as those showing LOH in primary tumour samples, they might be very useful for the identification of the specific genes involved. Moreover, LOH in 3p13-22 was also detected in ten out of 16 (62%) CC cell lines, which is consistent with the data obtained from primary tumours (Larson et al, 1997) .
Chromosome 4 in CC
There is experimental evidence suggesting that human chromosome 4 might be important in CC. The introduction of chromosome 4 into HeLa cells conferred a senescence phenotype (Ning et al, 1991) . Furthermore, the most common chromosome aberration is the detection of an isochromosome, i(4), in CC (Atkin et al, 1989) . Later, LOH studies identified at least two regions that are frequently involved in this tumour (Table 3) . One of them, in the short arm, 4p16, is consistent in all studies. The second, in the long arm, has been mapped to a larger area, 4q21-35, depending on the markers used. But the general conclusion is that two genes on this chromosome contribute to the cervical carcinoma phenotype Kersemaekers et al, 1998b) .
The short arm of chromosome 5 in CC
The first evidence indicating that chromosome 5 might be implicated in CC was detected in the HeLa cell line. This cell line has an isochromosome 5p with integrated HPV18 (Popescu et al, 1987) . Furthermore, the cytogenetic analysis of 43 cervical carcinomas, stages IIb-IV, also detected the presence of i(5p) in 75% of the cases, and frequently there were two copies of this isochromosome (Atkin et al, 1989) . Later, using comparative genome hybridization (CGH), amplification of 5p was detected in a large number of cases, particularly in advanced stages, from IIb to IV (Heselmeyer et al, 1997) , consistent with the cytogenetic evidence. All these data suggest a dose effect of a gene located on 5p. However, LOH studies on this chromosome have revealed a low number of affected loci (Mullokandov et al, 1996; Kersemaekers et al, 1998b) .
Chromosome 6 in CC
Several studies have identified a very high incidence (41%) of LOH in the short arm of chromosome 6p21.3-p25 (Mitra et al, 1994a; Mullokandov et al, 1996; Huettner et al, 1998; Kersemaekers et al, 1998b) . Some groups identify two independent regions with LOH, 6p21.3 and 6p24 (Kersemaekers et al, 1998b) . Among the candidate altered genes is TNF-α on 6p21.3. Using markers for this gene, LOH was detected in 17 out of 43 (40%) cases of FIGO stages I and II lesions (Kersemaekers et al, 1998b) . Although there is still no functional evidence for the role of TNF-α in cervical carcinoma, its alteration is likely to make tumour cells less sensitive to the induction of apoptosis and therefore promote their survival (Hueber et al, 1997; Krammer, 1997) .
Chromosome 11 in CC
Three lines of work support the importance of human chromosome 11 in cervical cancer, all of them pointing to the presence of a tumour suppressor gene that plays a fundamental role in this tumour phenotype. The initial evidence came from somatic cell genetics. The fusion of HeLa cells (with integrated HPV18) or SiHa cells (with integrated HPV16), with microcells containing human chromosome 11, resulted in the generation of cell hybrids that have lost their tumorigenic properties in nude mice, but if these hybrids lost the introduced chromosome 11 they regained their tumorigenic phenotype (Saxon et al, 1986; Koi et al, 1989; Oshimura et al, 1990) . Furthermore, the progression towards immortalization of human keratinocytes transfected with either HPV16 or HPV18 was accompanied by allele losses at 11q (Steenbergen et al, 1996) , and cytogenetic studies of cervical carcinomas detected that chromosome 11 is underrepresented (Southern and Herrington, 1997) . Two different regions with LOH have been identified in chromosome 11, one on each arm (Srivasan et al, 1991; Hampton et al, 1994; Mitra et al, 1994a; Bethwaite et al, 1995; Mullokandov et al, 1996; Kersemaekers et al, 1998a Kersemaekers et al, , 1998b . Two groups detected LOH in 12 out of 43 cases (28%) in the 11p15 region, but could not show that the Wilms' tumour (WT1) suppressor gene is implicated in these carcinomas (Mitra et al, 1994a; Mullokandov et al, 1996) . Other groups detected LOH in 11q22-24 (Table 3) . The region where this putative tumour suppressor gene might be was narrowed down to 11q23 (Hampton et al, 1994; Bethwaite et al, 1995; Mullokandov et al, 1996; Kersemaekers et al, 1998a) . LOH at 11q23 has a strong correlation with the presence of an invasive carcinoma at FIGO stages I and II (Kersemaekers et al, 1998b) . However, it is not known if any of these two regions are the ones that revert the tumorigenic phenotype of HeLa and SiHa cells.
LOH in chromosome 17 and lack of mutations in p53
Chromosome 17 was the first to attract attention in cervical carcinoma because it contains the TP53 gene in its p13.3 band, which is frequently mutated in many types of tumours (Greeblatt et al, 1994) . Therefore, several studies have attempted to determine if this chromosome region is altered. The frequency of LOH at 17p13.3 is 24% (Table 3) , and most often did not affect the TP53 locus. Thus, suggesting the candidate tumour suppressor gene in this region must be different from TP53 (Park et al, 1995) , evidence for this new gene has been recently found in lung cancer (Konishi et al, 1998) . Several studies have also attempted to correlate TP53 mutations with the HPV status of the tumour. p53 appears to be more frequently mutated in HPV-negative tumours, but this negativity has been questioned since nowadays all tumours are considered HPV-positive (Bosch et al, 1995) . The frequency of mutation is rather low, less than 10%, in CC (Fujita et al, 1992; Castren et al, 1998; Helland et al, 1998a ) when compared to mutations in other tumours, such as lung or colon carcinomas (Greeblatt et al, 1994) . This lack of mutations has lent support to the interpretation that mechanism implicated in these tumours is likely to be a consequence of the interaction of HPV E6 viral protein with p53 protein (Figure 1) , and by which they could achieve a biological situation resembling a partial p53 defect.
Overexpression of p53 may be found in cases of CC negative for HPV (Helland et al, 1998a) . The analysis of the expression of p53 protein in cervical lesions detected a high level of p53 expression in low-grade SIL lesions and in lesions with HPV 6/11/42 (86%) (Kurvinen et al, 1996) . But in high-grade SIL or HPV16/18-positive lesions the level of p53 was absent or detected in only a few cells (Kurvinen et al, 1996) . These authors found no correlation of lesion with mdm2 protein antigen level. In the same study the bcl2 protein was confined to basal cells in normal epithelium, and in hSIL lesions positive for HPV16/18 bcl2 appeared located on suprabasal cells (Kurvinen et al, 1996) .
Chromosome 18 and 19 recurrent LOH in CC
In two other chromosomes, 18 and 19, LOH have been detected in two different regions, although these chromosomes have been studied in less detail. In chromosome 18 LOH within 18q21 region was detected in 24% of the cases (Table 3) , and in a smaller proportion in 18p11 band, 22 out of 172 cases (12%) (Mitra et al, 1994a; Mullokandov et al, 1996; Huettner et al, 1998; Kersemaekers et al, 1998b) . There is no information regarding the possible genes affected.
On chromosome 19 there are also two LOH regions, although their frequency is lower than 20%. LOH has been detected in 19q12-13 (Mullokandov et al, 1996; Huettner et al, 1998; Kersemaekers et al, 1998b ) and 19p13 (Mullokandov et al, 1996; Huettner et al, 1998; Kersemaekers et al, 1998b) , which are the breakpoints of the two chromosome 19 regions frequently involved in chromosomal translocations (Mitelman et al, 1997) .
Recurrent point mutations in CC
There have been several studies attempting to detect mutations in genes well known to have point mutations in other tumours, including H-RAS, TP53, p16INK4A, p15INK4B RB and other cell cycle genes. These were tested in both HPV-positive and -negative cells. Some mutations have been detected in H-RAS (Dokianakis et al, 1998; Leis et al, 1998) . The p15 and p16 genes, both on chromosome 9p21 and separated by 25 kilobases, do not present mutations in CC (Kim et al, 1998) . However, it is not known if the p19ARF gene, which shares exons with p16 and which appears to be the cause of the phenotype previously attributed to p16, is affected (Kamijo et al, 1997) . The data on TP53 are dealt with in the section on chromosome 17.
Recurrent amplifications and chromosome gain
Gene amplification and chromosome gain are two different mechanisms by which a tumour cell can increase a gene dosage. In a study of 22 protooncogenes in 50 primary untreated squamous cell carcinomas of the uterine cervix, clinical stages II and III, only 12 (24%) have some amplifications (Mitra et al, 1994a (Mitra et al, , 1994b . Fivefold or larger amplifications were found for MYCL1, SEA, CCND1, BCL1 and GLI genes in one case (2%); HRAS was amplified in two cases (4%); and ERBB2 in seven cases (14%). SEA, CCND1 and BCL1 map to band 11q13 and might be within a unique amplicon. Two of the ERBB2 cases also showed rearrangement of the 17q11.2-12 band, suggesting a possible damage of this gene. Overexpression of ERBB2 gene has been previously reported in 60% of the cases studied (Pinion et al, 1991) . ERB2/neu amplification has been observed in other carcinomas, including breast and ovary (Mitra et al, 1994b) . The protooncogenes that have been studied and that showed no amplification were: NMYC, RAF1, KIT, ROS1, EGFR, MDR1, MET, MYC, INT2, KRAS2, ETS1, WNTI, MDM2, SRC and PDGF. The uterine cervix has been used to study chromosomal aberrations during the transition from premalignant to invasive carcinoma (Heselmeyer et al, 1996) . CC has well-defined progression steps based on cytology that are useful for correlation with genetic aberrations. These authors studied normal cervical epithelium, mild, moderate and severe dysplasias as well as CC. The first alteration detected when there is an increase in cell proliferation is the appearance of tetraploidy. No other recurrent aberration was observed in the transition from normal to moderate dysplasia. In one severe dysplasia a gain of 3q (one out of 13) was observed. In invasive carcinomas a gain of 3q was detected in nine out of ten cases (90%). Thus, gain of 3q can be considered a late and important alteration for the developments of invasive cervical carcinoma. The smaller common region of amplification has been reduced to band 3q24-28 (Heselmeyer et al, 1996) .
Microsatellite instability and mutator phenotype
Alterations in DNA repair genes result in the accumulation of mutations, some of which are important for tumour development. DNA repair genes belong to a family of genes designated as caretaker genes . The phenotype of mutations in this type of genes is detected by microsatellite instability (MI). The cell with a defect in any of these genes will invariably progress to develop a cancer . In a study of 89 primary tumours, ten cervical carcinoma cell lines and 30 loci located on 3p, 4 and 11q were analysed for MI. Three out of 89 tumours (3.3%) exhibited novel tumour-specific alleles at 77, 70 and 60% of the loci studied respectively . Two other tumours also have some MI using additional markers, bringing the total to 5/89 (5.6%). In this work the implication of the hMLH1, in 3p21, was ruled out. Also one cell line, C33A which is negative for HPV, presented this mutator phenotype, with new alleles in 30 of 84 markers determined . In another study, alterations at eight dinucleotide loci mapping to six different chromosomes were found in five out of 82 cervical cancers (Helland et al, 1997; Kersemaekers et al, 1998a) . In another 51 cases, mutator phenotypes were detected in four cases (Ku J-L et al, 1977; Ku W-H et al, 1997) . This instability affected to one or two alleles at one or few loci. The use of semiautomated fluorescence-based detection allowed the identification of additional five out of 58 cases showing MI . A more recent study has found microsatellite instability in a larger number of cases, in nine out of 64 cases (14%) (Kersemaekers et al, 1998a) .
Overall, of 344 cases analysed for the presence of the mutator phenotype, only 28 displayed MI (8%), independently of the type of allele and number of chromosomes studied (Ku J-L et al, 1977; Larson et al, 1996; Helland, 1997; Ku W-H et al, 1997) , which represents a small subset of the total number of CC cases.
Multiple genetic changes in CC: combined genetic alterations in individual tumours
Based on the multigenic nature of cancer it should be expected that there must be several genetic alterations in a single tumour. These alterations might have occurred with an order of selection depending on the stage where their phenotypic consequences are required for the development and progression of the carcinomas. The genetic analysis of CC in this context is rather limited. But there is enough information pointing to the multigenic nature of the process. In addition to viral DNA integration is present in all CC (Bosch et al, 1995) . Two studies have detected multiple LOH in several tumours (Mitra et al, 1994a; Mullokandov et al, 1996) . The number of LOH per tumour ranged from one to ten, with an average number of four and a standard deviation of two, for 52 cases (Mitra et al, 1994a) . Some of the locations appear consistently in independent studies, but two of them are particularly striking, those occurring in chromosomes 3 and 11. Also, some of these LOH regions coincide with reported regions of HPV DNA integration as is the case for chromosome regions 5p, 3p and 8q. In the HeLa cell line there are alterations in four oncogenic regions, 5p11-15, 8q24, 9q31-34 and 22q12-13, surprisingly all of them with integrated viral DNA (Popescu and DiPaolo, 1989) . A very recent study using CGH has detected some of these combinations of genetic alterations in different types of cervical lesions (Kirchhoff et al, 1999) .
In experimental immortalization of human keratinocytes with HPV 16 and HPV 18 there is LOH at chromosome region 3p (Montgomery et al, 1995; Steenbergen et al, 1996) , which is combined with losses at chromosome arms 11q, 18q or 10p (Steenbergen et al, 1996) , some of which have also been detected in primary tumours.
Other factors: genetic predisposition, the role of the HLA system
In the pathogenesis of HPV-infected cells there are several aspects that appear to be a consequence of the host immune response, such as the reversion of lesions. The study of HLA haplotypes in a case control study has demonstrated that in CIN II-III lesions certain class II haplotypes, such as DQA1*0102 and DQB1*0602, are overrepresented (Helland et al, 1998b) . Considering the widespread HPV-infected population, this observation might mean that certain haplotypes might be more efficient than others in triggering a host response that will eliminate the HPV-infected cells. The overrepresented HLA alleles may be those that are less effective in triggering a response against the HPV-infected cell. Thus, the HPV infection that is highly prevalent starts to skew the representation of HLA alleles as the disease progresses. This might be a reflection of the host immune response to the presence of HPV. Therefore, the HLA haplotype is an important factor at the initial stage of the disease because it influences the point between reversion and progression of the HPV-induced lesion. Furthermore, in CC there is a down-regulation of class I antigens in tumour cells, thus minimizing the consequences of a possible anti-tumour cell-mediated response by the host immune system (Bartholomew et al, 1997) .
The host immune response can also be influenced by the type of viral antigens that might be produced during disease progression. In the initial infection with possible production of viral particles, the main viral antigens are likely to be derived from the L1 and L2 capsid proteins. However, in CC with integrated HPV DNA, the viral L1 and L2 genes are lost, and the epitopes available will be derived from the intracellular expression of the viral E6 and E7 proteins. Thus, depending on the stage of the disease, the type of host immune response directed against HPV-containing cells is likely to be different. These differential viral protein expressions will have to be taken into account for the design of HPV vaccines. In lesions with integrated viral DNA and consequent loss of viral L1 and L2 genes, the immune response will have to be against peptides derived from the E6 and E7 viral proteins.
GENETIC DAMAGE AND CERVICAL LESION STAGING
The ultimate goal of the identification of genetic damage implicated in CC would be to understand its role within the biology of this tumour phenotype and to translate this information in such a way that at diagnosis stage one could predict the evolution and outcome of the tumour depending on the mutations detected. At this moment few specific LOH have been correlated with any particular stage (Figure 2 ), but it is expected that in a few years, instead of LOH we will be talking about specific genes and particular tumour cell properties. Today, some of the genetic damage can be correlated with some stages along the progression of the lesion, thus indicating the stage for which their phenotypic contribution is important. Some genetic alterations such as viral DNA integration, presence of an isochromosome i(5p), 3q amplification and LOH at 3p13-21 and 11q23 are important contributors for the development of an invasive carcinoma. The timing of these genetic alterations is presented in Figure 2 . The day that specific mutations can be identified routinely in a clinical setting is likely to improve the management of specific tumour types because of its potentially predictable value.
Few studies have so far addressed the possible correlation between LOH and tumour stage and evolution. For example, LOH at 11q23 appears to correlate with extensive lymphovascular space invasion, and these tumours tend to recur (Huettner et al, 1998) , and tumours with LOH on 18q have a relatively poor survival (Kersemaekers et al, 1998b) . The next step will be to identify which gene in each chromosome region is the relevant one for cervical carcinoma, and to determine at what stage of tumour development they contribute. Thus they will become markers of specific properties related to tumour progression, and this knowledge we hope will contribute to improve management of the patients.
